Loading...
Lung Cancer2023-12-01T16:40:59+01:00

ASCO Lung Cancer 2023 – hybrid, Chicago

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASCO 2023 – lung cancer

ASCO 2023 Lung Cancer English Download

Full report (english)

EXPERT VIDEOS

All video interviews from ASCO Lung Cancer 2023

John Heymach provides an overview on the expected benefits of HER2-selective tyrosine kinase inhibitors compared to anti-HER2-antibodies while highlighting the Beamion Lung 1 data. Moreover, he talks about RET inhibitor sensitivity and resistance in lung cancer and shares which study, presented at this year’s ASCO congress, is most likely to impact standard of care treatment in NSCLC.

Marjorie G. Zauderer explains the correlations between histopathological features and genetics in the setting of malignant mesothelioma, and the potential benefit of studying therapeutically relevant subgroups of patients separately, critically discusses trails using PD-1 checkpoint inhibition in unresectable mesothelioma and once again encourages everyone to explore the poster sessions at the major conferences to interact with colleagues around the world.

ASCO Lung Cancer 2022 – hybrid, Chicago

 

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASCO 2022 – lung cancer

ASCO 2021 English Download

Full report (english)

EXPERT VIDEOS

All video interviews from ASCO Lung Cancer 2022

John Varlotto summarizes the insights that have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable, locally advanced stage III non-small cell lung cancer, explains the different effect observed with pembrolizumab and nivolumab and how these results compare to existing data. He cautions against using the impressive pathologic complete response rates with neoadjuvant chemoimmunotherapy to the unresectable setting due to the lack of long-term survival rates with neo-adjuvant chemo/immunotherapy and the impressive 47.5 median overall survival noted with concurrent chemo/radiotherapy followed by consolidative durvalumab in the Pacific Trial.

Jessica Donington highlights the most promising agents currently investigated in the neoadjuvant setting in patients with resectable NSCLC, how the “intensity” of neoadjuvant treatment affects the outcomes and discusses if neoadjuvant chemo-immunotherapy is the new standard of care. She outlines which variables related to surgery itself are determinants of the success of curative surgery and which biomarkers are on the rise to guide therapy.

ASCO Lung Cancer 2021 – virtual

 

Lecture Board: Maximilian Hochmair, MD; Donald Harvey, PharmD; Martin Reck, MD, PhD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASCO 2021 – lung cancer

ASCO 2021 English Download

Full report (english)

ASCO 2021 Mandarin Download

Full report (mandarin)

ASCO 2021 Japanese Download

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO Lung Cancer 2021

Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.

David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.

Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.

Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.

Luis G. Paz-Ares explains which notable developments are taking place in the field of small-cell lung cancer with respect to new targets and targeted agents, how chemotherapeutic standards will change in the management of patients with small-cell lung cancer and highlights the most relevant findings presented at ASCO 2021 in terms of targeted therapies.

ASCO 2020 – virtual

Lecture Board: D. Ross Camidge, MD, PhD; Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASCO 2020

ASCO 2020

Full report (english)

memo inOncology ASCO 2020 mandarin

Full report (mandarin)

ASCO 2020 Japanese

Full report (japanese)

A range of relevant and potentially practice-changing findings was presented in the field of lung cancer. Immunotherapy and targeted-therapy strategies are now being explored either before or after surgery for early stage disease, with multiple challenges in determining what is and is not a transformative approach. (ASCO 2020)

D. Ross Camidge • MD • PhD, Director of Thoracic Oncology, University of Colorado, Aurora, Colorado, USA National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)

ASCO 2019 – Chicago

Lecture Board: Rafał Dziadziuszko, MD, PhD; Enriqueta Felip, MD, PhD; Maximilian Hochmair, MD; Sanjay Popat, PhD, FRCP; Elisabeth Quoix, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ASCO 2019

memo_InOncology_Special_ASCO_2019_Eng

Full report (english)

memo_InOncology_Special_ASCO_2019_Mandarin

Full report (mandarin)

memo_InOncology_Special_ASCO_2019_japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2019

Martin Reck gives an overview on where we are today regarding immunotherapies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.

Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.

Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.

Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.

In the area of target therapies, novel agents as well as combinations of established drugs will most likely define new standards for patients with advanced NSCLC in the years to come. (ASCO 2019)

Elisabeth Quoix • MD, Dep. of Pneumology, Hopitaux Universitaires de Strasbourg

ASCO 2018 – Chicago

Lecture Board: Maximilian Hochmair, MD; Bruce E. Johnson, MD; Barbara Melosky, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ASCO 2018

ASCO 2018 English

Full report (english)

ASCO 2018 Mandarin

Full report (mandarin)

ASCO 2018 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2018

Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.

Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.

Today, nearly half of all patients presenting with advanced lung cancer can receive initial treatment with oral targeted agents or immunotherapy, rather than chemotherapy. I am optimistic that a subset of our lung cancer patients might actually be cured with checkpoint inhibitor therapy. (ASCO 2018)

Bruce E. Johnson • MD •, President, American Society of Clinical Oncology Chief Clinical Research Officer, Dana-Farber Cancer Institute, Boston, MA, USA ASCO Translational Research Professor

ASCO 2017 – Chicago

Lecture Board: Martin Filipits, MD; Maximilian Hochmair, MD; Anna Nowak, PhD; Egbert Smit, MD, PhD; Johan Vansteenkiste, MD, PhD; Yi-Long Wu, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ASCO 2017

ASCO 2017 English

Full report (english)

ASCO 2017 Mandarin

Full report (mandarin)

ASCO 2017 Japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2017

Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.

Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.

Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.

Maya Gottfried on NSCLC screening and treatment options.

Immunotherapy is an emerging standard in lung cancer management, which is corroborated by the trial updates presented at ASCO 2017, many revealing durable treatment benefit over extended periods. (ASCO 2017)

Anna Nowak • MBBS • FRACP • PhD

ASCO 2016 – Chicago

Lecture Board: Paul A. Bunn Jr., MD; Maximilian Hochmair, MD; Nir Peled, MD; Gustavo Werutsky; MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ASCO 2016

ASCO 2016 English

Full report (english)

ASCO 2016 Mandarin

Full report (mandarin)

ASCO 2016 Spanish

Full report (spanish)

One quarter of the abstracts submitted for this year’s ASCO Congress were focussed on the topic of immunotherapy. According to updates of pivotal trials, sustained benefits can be expected in a minority of patients with these drugs. (ASCO 2016)

Paul A. Bunn Jr. • MD • FASCO, Distinguished Professor and James Dudley Chair of Lung Cancer Research, University of Colorado Cancer Center, Aurora, Colorado, USA. 2016 David A. Karnofsky Memorial Award Winner

ASCO 2015 – Chicago

Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ASCO 2015

ASCO 2015 English

Full report (english)

The chapters presented in this publication summarise the recent findings in the fields of metastatic non–small-cell lung cancer (NSCLC), immunotherapy, SCLC, biomarkers, and local and regional lung cancer. Naturally, targeted agents are the ‘stars’ of the coverage, but other long-standing strategies, such as chemotherapy and radiotherapy, enter the stage as well. (ASCO 2015)

Barbara Melosky, • MD • FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada
Go to Top